Table 1.
Summary of positive autoreactive tests
| Autoreactive | HD | OUT | ICU | ICU-PASC | ARDS | SLE |
|---|---|---|---|---|---|---|
| Target | (n = 14) | (n = 18) | (n = 27) | (n = 40) | (n = 29) | (n = 20) |
| dsDNA | 0 | 0 | 0 | 1 (3%) | 18 (90%) | |
| ANA titre | 2 (14%) | 1 (6%) | 11 (41%) | 16 (40%) | 18 (62%) | 20 (100%) |
| Sm | 0 | 0 | 0 | 0 | 0 | 6 (30%) |
| Ro52 | 0 | 0 | 1 (4%) | 0 | 1 (3%) | 12 (60%) |
| Ro60 | 1 (7%) | 0 | 0 | 0 | 0 | 13 (65%) |
| La | 0 | 0 | 0 | 0 | 0 | 3 (15%) |
| Jo | 0 | 0 | 0 | 0 | 0 | 0 |
| Ribonucleoprotein | 0 | 0 | 0 | 0 | 0 | 14 (70%) |
| Ribosomal protein | 0 | 0 | 0 | 1 (3%) | 0 | 6 (30%) |
| RNA Pol 3 IgG | 0 | 0 | 2 (7%) | 4 (10%) | 2 (7%) | 8 (40%) |
| RF IgM | 0 | 1 (6%) | 2 (7%) | 2 (5%) | 4 (14%) | 8 (40%) |
| RF IgA | 0 | 0 | 0 | 0 | 2 (7%) | 4 (20%) |
| Citulinated protein | 0 | 0 | 1 (4%) | 0 | 3 (10%) | 3 (15%) |
| Prothrombin IgM | 0 | 2 (11%) | 4 (15%) | 1 (3%) | 0 | 4 (20%) |
| Prothrombin IgG | 0 | 0 | 0 | 1 (3%) | 0 | 7 (35%) |
| Cardiolipin IgM | 0 | 0 | 0 | 0 | 1 (3%) | 0 |
| Cardiolipin IgA | 0 | 0 | 0 | 0 | 2 (7%) | 1 (5%) |
| Cardiolipin IgG | 0 | 2 (11%) | 2 (7%) | 1 (3%) | 2 (7%) | 1 (5%) |
| B2GP1 IgM | 0 | 0 | 0 | 0 | 0 | 0 |
| B2GP1 IgA | 0 | 0 | 0 | 0 | 0 | 1 (5%) |
| B2GP1 IgG | 0 | 1 (6%) | 1 (4%) | 2 (5%) | 1 (3%) | 3 (15%) |
| MPO | 0 | 0 | 0 | 0 | 0 | 0 |
| PR3 | 0 | 0 | 0 | 0 | 1 (3%) | 0 |
| ANCA | 0 | 0 | 3 (11%) | 4 (10%) | 1 (3%) | 12 (60%) |
| p70 | 0 | 0 | 0 | 0 | 1 (3%) | 9 (45%) |
| Carbamylated protein | 0 | 0 | 11 (41%) | 10 (25%) | 11 (38%) | 14 (70%) |
| GBM | 0 | 0 | 2 (7%) | 0 | 1 (3%) | 0 |